Salute e Benessere

COSRX Announces Prime Big Deal Days Promotion Featuring the Advanced Snail Duo…

A Skincare Must-Have for #MirrorSkin A Skincare Must-Have for #MirrorSkin TheAdvanced Snail 96 Mucin Power Essencedelivers deep hydration, locking in moisture to enhance the skin's natural radiance. With 96% snail mucin, it works to smooth skin texture and boost elasticity, making it an essential step in your skincare routine. To take your skincare routine one step further, follow with theAdvanced Snail 92 All in one Cream. This cream intensifies the moisture barrier, seals in...
PR Newswire
07/10/2024

NTC Launches Imperial, the new eye drops product line on THE PATIENT'S SIDE

NTC is going to present the Imperial line during CPhI in Milan, supporting with evidence the innovation of this device characterized by exceptional drop control for precise dosing, elongated tip for a greater accuracy in instillation, and advanced ergonomics to assure a low squeeze force bottle. NTC is going to present the Imperial line during CPhI inMilan, supporting with evidence the innovation of this device characterized by exceptional drop control for precise dosing, elongated tip for a...
PR Newswire
07/10/2024

Buyback of Class B shares in Essity during week 40, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
07/10/2024

Sai Life Sciences releases Sustainability Report 2024

Contract Research, Development and Manufacturing Organization (CRDMO) [1] , published itsSustainability Report for 2023-2024. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, this fifth edition of the Sustainability Report is based on the theme,'Synergising Sustainability, Performance and Growth.'The full report can be readhere.Making the announcement,Krishna Kanumuri, CEO & Managing Directorof Sai Life Sciences,...
Nasdaq GlobeNewswire
07/10/2024

Immunovia has successfully acquired all blood samples required to clinically…

Immunovia has secured over 1,000 blood samples, including over 200 from patients with stage 1 and 2 pancreatic cancer and more than 800 blood samples from high-risk individuals without cancer. The study will be one of the largest clinical validation studies of a pancreatic cancer biomarker test conducted to date. Immunovia has secured over 1,000 blood samples, including over 200 from patients with stage 1 and 2 pancreatic cancer and more than 800 blood samples from high-risk individuals without…
PR Newswire
07/10/2024

Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by…

Importantly, HNSA-5487 demonstrated lower pre-treatment anti-drug antibody (ADA) levels and significantly reduced ADA responses when compared to imlifidase, confirming an attractive immunogenicity profile with a clear redosing potential. HNSA-5487 also demonstrated highly robust reduction in IgG levels with similar efficacy in nearly 100 percent of serum samples collected in the trial and analyzed at six- and 12-months after the initial dose. Importantly, HNSA-5487 demonstrated lower...
PR Newswire
07/10/2024

Siloam Hospitals Group and Philips sign AI capability MoU to support Indonesia's…

Jakarta, Indonesia and Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Siloam Hospitals Group, Indonesia's leading private healthcare provider, have signed a Memorandum of Understanding (MoU) to advance AI capabilities and development in the healthcare sector in Indonesia.The strategic collaboration, in partnership with the Universitas Pelita Harapan (UPH) Medical Sciences Group, will focus on capacity building, knowledge...
Nasdaq GlobeNewswire
07/10/2024

Lesaffre strengthens its Research, Development & Innovation (RD&I) with the…

"At Lesaffre, we are driven by an unwavering belief in the infinite possibilities of fermentation," says Brice-Audren Riché, CEO of Lesaffre. "Powered by the incredible potential of microorganisms, we see fermentation as a transformative solution to nourish a growing global population in a safer, healthier, and more sustainable way. As a leader in bioengineering and bioprocesses, we naturally place research, development, and innovation at the heart of our success. Our strong…
PR Newswire
07/10/2024

International Experts Highlight Pleiotropic Benefits of Vitamin D Beyond Bone…

Extraskeletal Vitamin D – The experts' opinion on this point is unanimous: vitamin D is not just involved in the skeletal system, which is the current focus of most guidelines and consensus statements issued by the scientific community. «Vitamin D functions as a hormone: it is only partially taken in through food and is produced by our body mainly through the cutaneous synthesis of cholecalciferol in response to exposure to solar radiation. And it has a pleiotropic effect, i.e. it can act on…
PR Newswire
07/10/2024

Mérieux NutriSciences Enters Agreement to Acquire Worldwide Food Testing…

Building on Mérieux NutriSciences' existing worldwide presence and reputation for delivering high-value, science-based solutions to its customers, this acquisition will enhance its global footprint, extending its operations to 32 countries, and doubling its presence in Canada and the Asia Pacific region. Building on Mérieux NutriSciences' existing worldwide presence and reputation for delivering high-value, science-based solutions to its customers, this acquisition will enhance its global...
PR Newswire
07/10/2024

IMU Biosciences joins ground-breaking UK research consortium investigating…

PRESS RELEASE IMU Biosciences joins ground-breaking UK research consortium investigating patient response tocancer immunotherapiesConsortium includes leading research institutions, NHS Trusts and industry members and aims to make pioneering immunotherapies safer and more effectiveLondon, UK, 7 October 2024– IMU Biosciences (or “the Company”), a biotechnology company pioneering systems-level immune profiling with AI to drive breakthroughs in precision medicine, is pleased to...
Nasdaq GlobeNewswire
07/10/2024

Medinol Announces Successful First-in-Human Implantation of ChampioNIR…

"We were impressed with ChampioNIR's deliverability and its straightforward deployment", said Prof. Gerard S Goh, Head of Interventional Radiology at The Alfred Hospital. "The Frictionless Deployment Mechanism made the precise positioning of the stent very straightforward". "We were impressed with ChampioNIR's deliverability and its straightforward deployment", said Prof. Gerard S Goh, Head of Interventional Radiology at The Alfred Hospital. "The Frictionless…
PR Newswire
07/10/2024

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line…

The Phase 1b part of the study evaluated three escalating doses of BerGenBio's selective AXL inhibitor bemcentinib in combination with standard chemo-immunotherapy (CIT), doublet chemotherapy and pembrolizumab, Keytruda®, for the 1L treatment of advanced/metastatic NSCLC patients. The primary endpoint was the assessment of the safety profile of the combination in NSCLC patients regardless of their STK11 mutational status. The Phase1bpart of the study evaluated three escalating doses of...
PR Newswire
07/10/2024

BioSenic S.A. : Transparency notification received from ABO Infinium Americas…

REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, October 7, 2024, 7:00 CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from ABO Infinium Americas OpCo LTD. The details of the transparency notification are set out below and the full text of the...
Nasdaq GlobeNewswire
07/10/2024

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic…

Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024.Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on ourForward, Faster...
Nasdaq GlobeNewswire
07/10/2024

Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda

[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024. WASHINGTON, Oct.05, 2024(GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has provided its investigational Marburg vaccine to Rwanda to support the ongoing outbreak response. The initial shipment of approximately 700 vaccine doses will be used in a trial targeting frontline workers, including healthcare professionals who have been hardest hit by the deadly virus. Sabin has entered...
Nasdaq GlobeNewswire
06/10/2024

BIOVAXYS ANNOUNCES CLOSING OF FIFTH TRANCHE OF PRIVATE PLACEMENT

The Company intends to use the proceeds of the Private Placement for general working capital purposes, including enabling the Company to fund and advance its business plans in regard to its successful recent acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by the former Canadian biotechnology…
PR Newswire
05/10/2024

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 –Genmab A/S(Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Baillie Gifford & Co has informed us that, as of October 3, 2024, Baillie Gifford & Co held the voting rights to 3,301,530 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S. About Genmab Genmab is an...
Nasdaq GlobeNewswire
04/10/2024

Bicomponent Fiber Market Size to Grow USD 6045.6 Million by 2030 at a CAGR of…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-36C357/Global_Bicomponent_Fiber_Market Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-36C357/Global_Bicomponent_Fiber_Market Major Factor : The bicomponent fiber market is experiencing robust growth due to increasing demand across various industries, including textiles, hygiene products, and automotive applications. Bicomponent fibers consist of two polymers with different properties,...
PR Newswire
04/10/2024

Peritoneal Dialysis Market to Hit USD 12.70 Billion by 2029 with 5.8% CAGR |…

Browse in-depth TOC on "Peritoneal Dialysis Market" Browse in-depth TOC on "Peritoneal Dialysis Market" 241 - Tables 66 - Figures 252 - Pages In this report, the peritoneal dialysis market has been segmented on the basis of offering, modality, disease indication, end user and region. The peritoneal dialysis market is segmented into peritoneal dialysis machines, solution bags, catheters, transfer sets, other peritoneal dialysis products and services on the basis of…
PR Newswire
04/10/2024

Ethypharm announces the appointment of Éric CHEVALIER as Group Human Resources…

Throughout his career, Éric Chevalier has held key positions in leading companies. In particular, he was Director of Human Resources at Biogen for 4 years, after having been HR Manager for several industrial organisations at General Electric Healthcare. He began his career at Coca-Cola Entreprises, where he spent nine years as an HR generalist. 20 years of experience have enabled him to acquire a comprehensive and integrated vision of HR, as well as solid expertise in the various key areas of…
PR Newswire
04/10/2024

Immatics Announces Upcoming Oral and Poster Presentations at the Society for…

Houston, Texas and Tuebingen, Germany, October 4, 2024–Immatics N.V.(NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39 thAnnual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024. Full abstracts will be available on November 5, 2024, at 9:00 am EST in...
Nasdaq GlobeNewswire
04/10/2024

Cyient DLM Expands Global Footprint with Strategic Acquisition of US-Based EMS…

This acquisition is in line with Cyient DLM's strategic roadmap to expand geographic footprint, add strategic clients and increase client proximity. This acquisition is in line with Cyient DLM's strategic roadmap to expand geographic footprint, add strategic clients and increase client proximity. Krishna Bodanapu, Executive Chairman of Cyient DLM, commented, "This acquisition is a pivotal moment for Cyient DLM. It expands our global footprint, brings us closer to our strategic customers,...
PR Newswire
04/10/2024

Inside information: Bioretec updates its product development strategy by…

The acceleration of product development of the RemeOs™ Spinal Interbody Cage will have an effect on the company's overall product development strategy, and Bioretec's board of directors has updated the company's financial targets in line with the revised overall product development strategy. Information on the updated financial targets will be published in a separate company announcement. The acceleration of product development of the RemeOs ™Spinal Interbody Cage will have an effect on the...
PR Newswire
04/10/2024
Altri  Comunicati